{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:05Z","timestamp":1786119485233,"version":"build-2736575974"},"reference-count":119,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/crd.0b013e3181d4e921","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T03:39:05Z","timestamp":1270784345000},"page":"148-162","source":"Crossref","is-referenced-by-count":56,"title":["Pharmacotherapeutic Management of Pulmonary Arterial Hypertension"],"prefix":"10.1097","volume":"18","author":[{"given":"Joe R.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Nawarskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a natural prospective registry.","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"R2-6-20210203","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry.","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-6-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension.","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"key":"R4-6-20210203","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982\u20132006.","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"},{"issue":"suppl","key":"R5-6-20210203","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension.","volume":"43","author":"Simonneau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R6-6-20210203","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study.","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"R7-6-20210203","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R8-6-20210203","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"R9-6-20210203","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension.","volume":"54","author":"Badesch","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R10-6-20210203","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"key":"R11-6-20210203","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension.","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-6-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension.","volume":"336","author":"Rubin","year":"1997","journal-title":"N Engl J Med"},{"key":"R13-6-20210203","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis.","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"R14-6-20210203","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"R15-6-20210203","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"R16-6-20210203","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"R17-6-20210203","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1378\/chest.111.6.1622","article-title":"A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD.","volume":"111","author":"Sajkov","year":"1997","journal-title":"Chest"},{"key":"R18-6-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/hrt.75.2.171","article-title":"Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension.","volume":"75","author":"Woodmansey","year":"1996","journal-title":"Heart"},{"key":"R19-6-20210203","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/eurheartj\/ehn234","article-title":"Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?","volume":"29","author":"Opitz","year":"2008","journal-title":"Eur Heart J"},{"key":"R20-6-20210203","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1165\/ajrcmb.20.4.3356","article-title":"Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats.","volume":"20","author":"Soma","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R21-6-20210203","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"R22-6-20210203","first-page":"H828","article-title":"Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats.","volume":"268","author":"Eddahibi","year":"1995","journal-title":"Am J Physiol"},{"key":"R23-6-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005344-200408000-00007","article-title":"Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats.","volume":"44","author":"Nishida","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R24-6-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000102534","article-title":"Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions.","volume":"44","author":"Sauvageau","year":"2007","journal-title":"J Vasc Res"},{"key":"R25-6-20210203","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3181\/00379727-231-2310840","article-title":"Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction.","volume":"231","author":"Sauvageau","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"R26-6-20210203","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/pupt.1998.0129","article-title":"Effect of novel mixed ETA\/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries.","volume":"11","author":"MacLean","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"R27-6-20210203","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.CIR.103.2.314","article-title":"Effectiveness of a nonselective ET(A\/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.","volume":"103","author":"Jasmin","year":"2001","journal-title":"Circulation"},{"key":"R28-6-20210203","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1183\/09031936.00078207","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension.","volume":"31","author":"Dupuis","year":"2008","journal-title":"Eur Respir J"},{"key":"R29-6-20210203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.CIR.102.4.411","article-title":"Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.","volume":"102","author":"Williamson","year":"2000","journal-title":"Circulation"},{"key":"R30-6-20210203","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-reecptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study.","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"R31-6-20210203","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R32-6-20210203","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"R33-6-20210203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension.","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"key":"R34-6-20210203","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"key":"R35-6-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.healun.2006.11.009","article-title":"Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.","volume":"26","author":"Keogh","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R36-6-20210203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","article-title":"Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.","volume":"73","author":"Barst","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R37-6-20210203","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2005.01.066","article-title":"Effects of long-term bosentan in children with pulmonary arterial hypertension.","volume":"46","author":"Rosenzweig","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R38-6-20210203","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","article-title":"Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.","volume":"170","author":"Sitbon","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"R39-6-20210203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1183\/09031936.00094808","article-title":"Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.","volume":"33","author":"Degano","year":"2009","journal-title":"Eur Respir J"},{"key":"R40-6-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind, randomized, placebo-controlled study.","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"R41-6-20210203","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R42-6-20210203","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.","volume":"67","author":"Denton","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R43-6-20210203","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R44-6-20210203","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension.","volume":"46","author":"Gali\u00e8","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R45-6-20210203","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"R46-6-20210203","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R47-6-20210203","first-page":"A3357","article-title":"ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract].","volume":"179","author":"Badesch","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R48-6-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension.","volume":"169","author":"Barst","year":"2004","journal-title":"Am Respir Crit Care Med"},{"key":"R49-6-20210203","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R50-6-20210203","article-title":"Tracleer prescribing information.","year":"2009"},{"key":"R51-6-20210203","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension.","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"key":"R52-6-20210203","article-title":"Letairis prescribing information.","year":"2009"},{"key":"R53-6-20210203","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"R54-6-20210203","article-title":"Thelin prescribing information.","year":"2008"},{"key":"R55-6-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","article-title":"Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.","volume":"60","author":"Paul","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R56-6-20210203","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"R57-6-20210203","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 3","key":"R58-6-20210203","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1378\/chest.114.3_Supplement.205S","article-title":"Lipid mediator dysregulation in primary pulmonary hypertension.","volume":"114","author":"Christman","year":"1998","journal-title":"Chest"},{"key":"R59-6-20210203","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension.","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"key":"R60-6-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.66.2.334","article-title":"Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.","volume":"66","author":"Rubin","year":"1982","journal-title":"Circulation"},{"key":"R61-6-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"R62-6-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) in primary pulmonary hypertension.","volume":"338","author":"McLaughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"R63-6-20210203","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.","volume":"30","author":"Shapiro","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"R64-6-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"R65-6-20210203","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R66-6-20210203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"R67-6-20210203","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension. The impact of epoprostenol therapy.","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"R68-6-20210203","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Prognostic factors and survival.","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R69-6-20210203","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"key":"R70-6-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","article-title":"A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension.","volume":"35","author":"Hoeper","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R71-6-20210203","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"R72-6-20210203","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension.","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"R73-6-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/hrt.79.2.175","article-title":"Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.","volume":"79","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"R74-6-20210203","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension.","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R75-6-20210203","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(97)24019-5","article-title":"Orally active prostacyclin analogue in primary pulmonary hypertension.","volume":"349","author":"Okano","year":"1997","journal-title":"Lancet"},{"key":"R76-6-20210203","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","article-title":"Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.","volume":"34","author":"Nagaya","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R77-6-20210203","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R78-6-20210203","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","article-title":"Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.","volume":"48","author":"Channick","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R79-6-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of iv treprostinil for pulmonary and arterial hypertension: a prospective, multicenter, open-label, 12-week trial.","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"R80-6-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension.","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"R81-6-20210203","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"R82-6-20210203","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"R83-6-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":"Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension.","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"R84-6-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R85-6-20210203","article-title":"Remodulin prescribing information.","year":"2008"},{"key":"R86-6-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2007.0657","article-title":"Inhaled prostanoids in the therapy of pulmonary hypertension.","volume":"21","author":"Gessler","year":"2008","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"R87-6-20210203","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"R88-6-20210203","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","article-title":"The L-arginine-nitric oxide pathway.","volume":"329","author":"Moncada","year":"1993","journal-title":"N Engl J Med"},{"key":"R89-6-20210203","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1073\/pnas.91.16.7583","article-title":"Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.","volume":"91","author":"Archer","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R90-6-20210203","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R91-6-20210203","article-title":"Revatio prescribing information.","year":"2009"},{"key":"R92-6-20210203","article-title":"Adcirca prescribing information.","year":"2009"},{"key":"R93-6-20210203","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R94-6-20210203","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.","volume":"151","author":"Singh","year":"2006","journal-title":"Am Heart J"},{"key":"R95-6-20210203","first-page":"2148","article-title":"Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2006;354:2400\u20132401].","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"R96-6-20210203","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/78.10.1207","article-title":"Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.","volume":"78","author":"Bhatia","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R97-6-20210203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","article-title":"Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.","volume":"42","author":"Ghofrani","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R98-6-20210203","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"R99-6-20210203","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjcard.2005.06.083","article-title":"Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.","volume":"96","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Cardiol"},{"key":"R100-6-20210203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1253\/circj.69.461","article-title":"Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol.","volume":"69","author":"Kataoka","year":"2005","journal-title":"Circ J"},{"key":"R101-6-20210203","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/hr.2009.113","article-title":"The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension.","volume":"32","author":"Xu","year":"2009","journal-title":"Hypertens Res"},{"key":"R102-6-20210203","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2147\/VHRM.S3210","article-title":"Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension.","volume":"4","author":"Keogh","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"R103-6-20210203","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"R104-6-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1291\/hypres.29.123","article-title":"Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension.","volume":"29","author":"Aizawa","year":"2006","journal-title":"Hypertens Res"},{"key":"R105-6-20210203","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","article-title":"Vardenafil therapy for patients with pulmonary arterial hypertension. A one-year, multicentre, open-label study.","volume":"95","author":"Jing","year":"2009","journal-title":"Heart"},{"key":"R107-6-20210203","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1368-5031.2006.00904.x","article-title":"Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.","volume":"60","author":"Gorkin","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R109-6-20210203","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/lary.20511","article-title":"Sudden hearing loss from PDE-5 inhibitors: a possible cellular stress etiology.","volume":"119","author":"Maddox","year":"2009","journal-title":"Laryngoscope"},{"key":"R110-6-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-007-0408-z","article-title":"Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.","volume":"64","author":"Burgess","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R111-6-20210203","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","article-title":"Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.","volume":"48","author":"Wrishko","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R112-6-20210203","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.","volume":"22","author":"Hoeper","year":"2003","journal-title":"Eur Resp J"},{"key":"R113-6-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"R114-6-20210203","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R115-6-20210203","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Resp J"},{"key":"R116-6-20210203","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1183\/09031936.00081706","article-title":"Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.","volume":"29","author":"Mathai","year":"2007","journal-title":"Eur Respir J"},{"issue":"suppl","key":"R117-6-20210203","first-page":"A3368","article-title":"Addition of sildenafil to first line bosentan therapy in patients with idiopathic pulmonary arterial hypertension [abstract].","volume":"179","author":"Savale","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R118-6-20210203","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension.","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"R119-6-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1440-1843.2007.01176.x","article-title":"Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.","volume":"13","author":"Bendayan","year":"2008","journal-title":"Respirology"},{"key":"R121-6-20210203","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"R122-6-20210203","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045415-201005000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:39Z","timestamp":1786040439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045415-201005000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0b013e3181d4e921","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}